论文部分内容阅读
表皮生长因子受体(epidermal growth factor receptor,EGFR)的发现和EGFR酪氨酸激酶抑制剂(EGFR tyrosine kinase inhibitors,EGFR TKIs)在敏感突变阳性肺癌患者中的应用,是肺癌治疗史上里程碑式的进展。与标准化疗相比,EGFR TKIs显著地延长了这类患者的无进展生存期,但所有患者都不可避免地会对EGFR TKIs产生耐药。为了克服耐药问题,应运而生的新型EGFR TKIs在作用靶点、结合方式以及临床疗效上均有一定程度的创新和突破,因而被称为“二代EGFR TKIs”。本文就二代EGFR TKIs在肺癌中的研究进展加以综述。
The discovery of epidermal growth factor receptor (EGFR) and the application of EGFR tyrosine kinase inhibitors (EGFR TKIs) in patients with sensitive mutation-positive lung cancer have been milestones in the history of lung cancer therapy . Compared with standard chemotherapy, EGFR TKIs significantly prolongs the progression-free survival of these patients, but all patients are inevitably resistant to EGFR TKIs. In order to overcome the drug resistance problem, the new EGFR TKIs came into being, which is known as “second-generation EGFR TKIs ” with some degree of innovation and breakthrough in its target, combination and clinical efficacy. This article reviews the research progress of the second generation EGFR TKIs in lung cancer.